TW204342B - - Google Patents

Download PDF

Info

Publication number
TW204342B
TW204342B TW081106123A TW81106123A TW204342B TW 204342 B TW204342 B TW 204342B TW 081106123 A TW081106123 A TW 081106123A TW 81106123 A TW81106123 A TW 81106123A TW 204342 B TW204342 B TW 204342B
Authority
TW
Taiwan
Prior art keywords
benzyl
hexahydropyridylamine
group
methyl
amine
Prior art date
Application number
TW081106123A
Other languages
English (en)
Chinese (zh)
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of TW204342B publication Critical patent/TW204342B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
TW081106123A 1991-08-12 1992-08-01 TW204342B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH237491 1991-08-12

Publications (1)

Publication Number Publication Date
TW204342B true TW204342B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-04-21

Family

ID=4232283

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081106123A TW204342B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-08-12 1992-08-01

Country Status (23)

Country Link
US (3) US5310743A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0532456B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3118090B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100261367B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE120456T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU660180B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2075684C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE59201771D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0532456T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2070617T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI104631B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3015954T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU221305B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL102769A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9204627A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY110227A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO303448B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ243888A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH29963A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2114829C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA94140632A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW204342B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA926013B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69300043T2 (de) * 1992-03-13 1995-05-24 Bio Mega Boehringer Ingelheim Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
CA2136999C (en) * 1993-04-07 2004-05-11 Takafumi Fujioka Peripheral vasodilating agent containing piperidine derivative as active ingredient
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
CA2198382A1 (en) * 1994-09-30 1996-04-11 Novartis Ag 1-acyl-4-aliphatylaminopiperidine compounds
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
BR9607335A (pt) * 1995-02-22 1997-11-25 Novartis Ag Compostos 1-aril-2-acrilamino-etano e seu uso como neuroquinina especialmente antogonistas de neuroquinina 1
RU2156250C2 (ru) * 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция
US6288225B1 (en) 1996-05-09 2001-09-11 Pfizer Inc Substituted benzolactam compounds as substance P antagonists
CA2226292C (en) 1995-07-07 2001-12-11 Pfizer Inc. Substituted benzolactam compounds as substance p antagonists
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
WO1997017957A1 (en) * 1995-11-13 1997-05-22 Smithkline Beecham Corporation Hemoregulatory compounds
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
NZ329953A (en) 1996-04-12 1999-06-29 Janssen Pharmaceutica Nv Substituted tetracyclic n-oxide tetrahydrofuran derivatives, salts and stereoisomeric forms thereof for the treatment of cns cardiovascular or gastrointestinal disorders
AU2898297A (en) * 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
EE04375B1 (et) * 1996-09-10 2004-10-15 Dr. Karl Thomae Gmbh Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod
CA2273807A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
EP0977572A1 (en) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Use of nk-1 receptor antagonists for treating eating disorders
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
AU738047B2 (en) * 1997-08-04 2001-09-06 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating mania
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
TW537894B (en) * 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
ES2198948T3 (es) * 1998-08-25 2004-02-01 Novartis Ag Usos de antagonistas de la substancia p para el tratamiento del sindrome de la fatiga cronica y/o de la fibromialgia.
FR2789390B3 (fr) * 1999-02-10 2001-03-09 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
UA71004C2 (uk) * 1999-05-21 2004-11-15 Пфайзер Продактс Інк. Похідні 1-трифторометил-4-гідрокси-7-піперидиніламінометилхроману
GB9917408D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
PT1246806E (pt) 1999-11-03 2008-04-03 Amr Technology Inc Tetra-hidroisoquinolinas aril- e heteroaril-substituídas e sua utilização no bloqueio da recaptação de norepinefrina, dopamina e serotonina.
AU2399601A (en) 1999-12-21 2001-07-03 Takeda Chemical Industries Ltd. Novel tachykinin-like polypeptides and use thereof
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
CA2417192A1 (en) 2000-07-26 2002-01-31 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
CA2438895A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
RU2311408C2 (ru) * 2001-12-03 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные аминотетралина в качестве антагонистов мускаринового рецептора
EP1470131A2 (en) * 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AR038240A1 (es) 2002-01-29 2005-01-05 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
JP2005522436A (ja) 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
RU2294927C2 (ru) * 2002-05-29 2007-03-10 Танабе Сейяку Ко., Лтд. Производные пиперидина, способы их получения, фармацевтическая композиция на их основе, их применение и способ лечения
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP2004285038A (ja) * 2002-05-31 2004-10-14 Takeda Chem Ind Ltd ピペリジン誘導体、その製造法および用途
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
WO2004056800A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
WO2004056805A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
JO2485B1 (en) 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
EP1693367A4 (en) 2003-11-28 2008-10-29 Mitsubishi Tanabe Pharma Corp PIPERIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
MY142362A (en) 2004-01-29 2010-11-30 Otsuka Pharma Co Ltd Pharmaceutical composition for promoting angiogenesis
US7232831B2 (en) * 2004-03-22 2007-06-19 Mediquest Therapeutics, Inc. Tetrahydro-β-carboline compounds and use thereof
US20060063766A1 (en) 2004-07-15 2006-03-23 Molino Bruce F Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin
CA2599186C (en) 2005-03-08 2014-12-09 Janssen Pharmaceutica N.V. Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0607532D0 (en) * 2006-04-13 2006-05-24 Novartis Ag Organic compounds
MX2009000646A (es) * 2006-07-20 2009-01-29 Novartis Ag Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp).
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RS51780B (en) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. INDASOLS SUBSTITUTED BY AMIDE AS INHIBITORS OF POLY (ADP-Ribose) POLYMERASES (PARP)
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
JP2012513435A (ja) * 2008-12-23 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ７調節薬としてのジヒドロピリドンアミド
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
JP5764553B2 (ja) 2009-05-12 2015-08-19 アルバニー モレキュラー リサーチ， インコーポレイテッド ７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンおよびその使用
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
HRP20180002T1 (hr) 2012-11-28 2018-02-09 Merck Sharp & Dohme Corp. Kompozicije i postupci za liječenje karcinoma
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN116848238A (zh) * 2021-01-14 2023-10-03 阿雷克森制药公司 大环补体因子b抑制剂
CA3220039A1 (en) 2021-06-14 2022-12-22 Jr. David St. Jean Urea derivatives which can be used to treat cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5145967A (en) * 1989-04-20 1992-09-08 Anaquest, Inc. Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5126455A (en) * 1989-12-13 1992-06-30 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
CA2080249C (en) * 1990-05-31 1996-11-19 Dennis M. Godek Preparation of substituted piperidines
US5451586A (en) * 1990-06-01 1995-09-19 Pfizer Inc. 3-amino-2-aryl quinuclidines
CZ387492A3 (en) * 1990-09-28 1994-02-16 Pfizer Analogs of non-aromatic hetero cycles containing nitrogen with a condensed ring, process of their preparation and use

Also Published As

Publication number Publication date
AU2096592A (en) 1993-03-04
RU2114829C1 (ru) 1998-07-10
MY110227A (en) 1998-03-31
KR100261367B1 (ko) 2000-07-01
FI923575A7 (fi) 1993-02-13
FI923575A0 (fi) 1992-08-10
ES2070617T3 (es) 1995-06-01
ZA926013B (en) 1993-03-31
NO923123L (no) 1993-02-15
US5541195A (en) 1996-07-30
JPH07196649A (ja) 1995-08-01
CA2075684C (en) 2003-01-07
KR930004297A (ko) 1993-03-22
HU221305B1 (en) 2002-09-28
JP3118090B2 (ja) 2000-12-18
HU9202615D0 (en) 1992-10-28
US5310743A (en) 1994-05-10
EP0532456B1 (de) 1995-03-29
NO303448B1 (no) 1998-07-13
FI104631B (fi) 2000-03-15
SA94140632A (ar) 2005-12-03
NZ243888A (en) 1996-03-26
IL102769A (en) 1999-01-26
PH29963A (en) 1996-09-25
EP0532456A1 (de) 1993-03-17
NO973117L (no) 1993-02-15
HUT67088A (en) 1995-01-30
NO923123D0 (no) 1992-08-11
US5646144A (en) 1997-07-08
ATE120456T1 (de) 1995-04-15
DE59201771D1 (de) 1995-05-04
MX9204627A (es) 1993-04-01
DK0532456T3 (da) 1995-06-12
CA2075684A1 (en) 1993-02-13
GR3015954T3 (en) 1995-07-31
IL102769A0 (en) 1993-01-31
AU660180B2 (en) 1995-06-15
IL118750A0 (en) 1996-10-16
NO973117D0 (no) 1997-07-04

Similar Documents

Publication Publication Date Title
TW204342B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW438781B (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
TW462968B (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
TW418198B (en) Piperazine derivatives and pharmaceutical composition comparising the same
TW201733B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2005202257B2 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
JP3152440B2 (ja) ニューロキニンアンタゴニストとして有用な置換オキシム誘導体
TWI336699B (en) Stat3/5 activation inhibitor
TW210339B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW219363B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW380138B (en) Piperidine derivatives which are selective antagonists of the human NK3 receptor and their use as medicinal products
TW204336B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU624147B2 (en) 1-indolylalkyl-4-(substituted pyridinyl) piperazines
TW201308B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW200418857A (en) Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
JPH07501063A (ja) フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体
TW200304808A (en) N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
IE83893B1 (en) Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present
CA2573223A1 (en) Aromatic compound
BRPI0619349A2 (pt) agente antitumor, método para tratar ou prevenir tumor, e uso de um composto
AU684874B2 (en) Heterocyclic compounds for the treatment of cns and cardiovascular disorders
EP0797576A1 (en) Alkyl substituted piperadinyl and piperazinyl anti-aids compounds
TW415940B (en) Condensed cyclic carboxylic acid compound or salt thereof, and medical composition containing which
TW438777B (en) Compounds useful as NK1 and/or NK2 anagonists and the pharmaceutical composition and preparation process thereof
RU2293734C2 (ru) Трициклические противоопухолевые соединения, фармацевтическая композиция и способ лечения на их основе

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees